Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600824 | 0.79 | HTR3A (0.64) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL5154912 | 0.78 | HTR3A (0.62) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL373021 | 0.78 | HTR3A (1.00) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL4703304 | 0.77 | HTR3A (0.73) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL4704458 | 0.75 | HTR3A (0.58) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL5532880 | 0.73 | KCNH2 (0.73) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL4703068 | 0.73 | HTR3A (0.70) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL4699915 | 0.72 | HTR3A (0.69) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL1459339 | 0.72 | HTR3A (1.00) | HTR3ACHRNA7KCNH2CHRM4CHRM5 | |
| SCHEMBL4699052 | 0.72 | HTR3A (1.00) | HTR3ACHRNA7KCNH2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809094-B2 | N-FUSED HETERCYCLO-1,4- OR -1,5- DIAZABICYCLO DERIVATIVES; NICOTINIC RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM (CNS) | PFIZER INC | 2004-10-26 | — | — | US | claimed |
| US-7439236-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1219622-B1 | Pharmaceutical compositions for CNS and other disorders | PFIZER PROD INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | PFIZER INC | 2006-06-29 | — | — | US | disclosed |
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-6881734-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6809094-B2 | N-FUSED HETERCYCLO-1,4- OR -1,5- DIAZABICYCLO DERIVATIVES; NICOTINIC RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM (CNS) | PFIZER INC | 2004-10-26 | — | — | US | disclosed |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | O'NEILL BRIAN THOMAS (US) | 2002-07-04 | — | — | US | disclosed |
| EP-1219622-A2 | Pharmaceutical compositions for CNS and other disorders | Pfizer Products Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | HTR3A 144/4885CHRNA7 1/4885KCNH2 959/4885 |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | HTR3A 147/4885CHRNA7 1/4885KCNH2 1560/4885 |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | HTR3A 147/4885CHRNA7 1/4885KCNH2 1560/4885 |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | C1QBP, BCHE, BDNF | HTR3A 462/4885CHRNA7 75/4885KCNH2 1166/4885 |
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | CHRNA7, CHRNA5, CHRNA4 | HTR3A 238/4885CHRNA7 1/4885KCNH2 451/4885 |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | HTR3A 147/4885CHRNA7 1/4885KCNH2 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.